Pharmaceutical Technology

APRIL 10, 2023

Aviceda Therapeutics (Aviceda) has entered into a strategic partnership with the Patrick G Johnston Centre for Cancer Research at Queen’s University Belfast (QUB) for the development of next-generation glyco-immune therapeutics. The company strengthens the translational research collaboration between the US and Ireland.

Immunization 103

Immunization 103

Hospital Pharmacy Europe

AUGUST 22, 2023

An anti-IL17 peptide sequence has demonstrated high clinical efficacy in models of immune-mediated inflammatory conditions, warranting further clinical evaluation. In addition, when compared with secukinumab, the current gold-standard biologic, the anti-IL17 peptide gave rise to less off-target immune-related effects.

Immunization 52

Immunization Hospitals 52

Hospital Pharmacy Europe

JULY 17, 2023

Immune checkpoint inhibitors have transformed the management of non-small cell lung cancer, but how long should treatment be continued for optimal survival? It has long been recognised that a hallmark of cancer is immune evasion and that the immune system is held back by inhibitory immune checkpoint receptors and ligands.

Immunization 98

Immunization Hospitals FDA 98

Pharmaceutical Technology

JUNE 30, 2023

Immune Thrombocytopeniais under clinical development by NovelMed Therapeutics and currently in Phase I for Idiopathic Thrombocytopenic Purpura (Immune Thrombocytopenic Purpura).

Immunization 52

Immunization 52

Pharmaceutical Technology

APRIL 17, 2023

Clinical-stage biotechnology company Smart Immune has secured $5m in equity investment from the Bill & Melinda Gates Foundation for expediting the development of its thymus-empowered ProTcell platform for the treatment of cancer and infectious diseases. SMART 101 is produced from healthy donor-mobilised peripheral blood.

Immunization 52

Immunization 52

PharmaVoice

SEPTEMBER 11, 2023

After dropping its neuroscience program earlier this year, the clinical-stage oncology company is doubling down on a candidate targeting the MAPK pathway.

Immunization 98

Immunization 98

Drug Topics

JANUARY 17, 2023

The shift in immunization from primary care to pharmacy is your opportunity to improve outcomes and grow your business. Solutions that integrate directly with pharmacy management systems enable clinical decision support at the point of care. This whitepaper reveals how clinical decision support works in practice!

Immunization 98

Immunization 98

The People's Pharmacy

MAY 8, 2023

Most people would like to improve their immune function at this time of year. Extra Zinc and Immunity: Zinc is one of those minerals that gets very little respect. Extra Zinc and Immunity: Zinc is one of those minerals that gets very little respect. Yet this mineral is crucial for the immune system. Could extra zinc help?

Immunization 61

Immunization Nursing Homes 61

pharmaphorum

OCTOBER 26, 2022

has exited stealth with a $65 million Series A to create a new class of medicines that target novel I-O mechanisms, which free the body’s normal immunity against cancer. Called “immune normalisers”, these targets are drawn from an ongoing and interactive academic-biotech research alliance within the Yale School of Medicine.

Immunization 52

Immunization 52

Pharmaceutical Technology

FEBRUARY 8, 2024

NiKogene is under clinical development by Kian Immune Cell and currently in Phase I for Pediatric Diffuse Intrinsic Pontine Glioma.

Immunization 40

Immunization 40

pharmaphorum

AUGUST 20, 2021

Bristol Myers Squibb has exercised an option on an immune-modulating drug candidate developed by UK artificial intelligence specialist Exscientia, paying $20 million for the buy-in as part of their $1.2 The post BMS buys into AI-designed immune drug from Exscientia appeared first on. billion alliance.

Immunization 98

Immunization 98

pharmaphorum

AUGUST 2, 2022

In May, another amyloid targeting drug for Alzheimer’s disease – AC Immune and Roche’s crenezumab – missed the mark in another clinical trial and looked destined for the scrap heap like so many drugs in the class before it. The post AC Immune tries to resurrect crenezumab with new data delve appeared first on.

Immunization 52

Immunization 52

pharmaphorum

MARCH 15, 2021

MeMed CEO Dr. Eran Eden explores the relationship between the host immune response and SARS-CoV-2 infection and how technology could help personalise treatment strategies. One of these involves listening to what the body’s own immune system can tell us. This is made possible using ‘Advanced Host Immune Response Technologies’.

Immunization 71

Immunization Vaccines 71

pharmaphorum

OCTOBER 11, 2022

An intranasal formulation of AstraZeneca’s widely-used COVID-19 vaccine Vaxzevria has failed at the first hurdle, after results from a phase 1 trial found it was unable to stimulate a strong immune response to the virus. ” The post AstraZeneca’s intranasal COVID vaccine fails first clinical test appeared first on.

Vaccines 115

Vaccines Immunization 115

Pharmaceutical Technology

JULY 6, 2022

Scientists at the National Institutes of Health (NIH) unit National Institute of Neurological Disorders and Stroke (NINDS) have found that Covid-19-induced immune response could damage the blood vessels of the brain and may lead to short and long-term neurological symptoms. .

Immunization 64

Immunization 64

Pharmaceutical Technology

DECEMBER 20, 2023

LC-002 is under clinical development by Genetic Immunity and currently in Phase II for Human Immunodeficiency Virus (HIV) Infections (AIDS).

Immunization 40

Immunization 40

Digital Pharmacist

JULY 11, 2023

One effective strategy to achieve this is by offering top-notch clinical services that not only enhance patient care but also contribute to a significant revenue boost. Immunizations & Vaccinations Independent pharmacies are ideally positioned to provide convenient immunization services to their communities.

Independent Pharmacies 98

Independent Pharmacies Compounding Scheduling Appointments Prescription Filling 98

Drug Store News

OCTOBER 31, 2023

Customers and their families can conveniently get routine immunizations at select Rite Aid locations.

Immunization 111

Immunization 111

Drug Topics

OCTOBER 31, 2023

The combination vaccine produced robust immune responses from vaccine candidates in a phase 1/2 clinical trial.

Vaccines 200

Vaccines Immunization 200

pharmaphorum

DECEMBER 4, 2020

The 4 th Antigen Specific Immune Tolerance Digital Summit (ASIT) brings together industry representatives from the fields of autoimmunity, allergy, immuno-oncology and transplantation to tackle the complexities behind autoimmune disorders head on. The post 4th Antigen Specific Immune Tolerance Summit appeared first on.

Immunization 52

Immunization Medical Schools 52

Outsourcing Pharma

NOVEMBER 16, 2021

have received the green light from Health Canada for their Clinical Trial Application for VCTX210: an allogeneic, gene-edited, immune-evasive, stem cell-derived therapy for the treatment of type 1 diabetes (T1D). CRISPR Therapeutics and ViaCyte, Inc.

Immunization 111

Immunization 111

European Pharmaceutical Review

NOVEMBER 16, 2023

In the past couple of months, BeiGene has experienced regulatory progress for two of its oncology assets in clinical development. What is the main challenge in advancing a drug through the clinical development process? Clinical trials account for over 90 percent of the cost and time of developing a new medicine.

Immunization 52

Immunization 52

pharmaphorum

SEPTEMBER 7, 2020

A trial of Russia’s Sputnik V coronavirus vaccine has shown the jab produces an immune response, although the study was too small to produce conclusive findings, particularly on safety. For our vaccine, we use two different adenovirus vectors in a bid to avoid the immune system becoming immune to the vector.”.

Immunization 107

Immunization Vaccines Hospitals 107

Outsourcing Pharma

OCTOBER 21, 2020

The US agency has launched a large clinical trial to examine the viability of using immune modulators to treat patients hospitalized with COVID-19.

Immunization 55

Immunization Hospitals 55

Pharmaceutical Technology

MARCH 2, 2023

Povetacicept is under clinical development by Alpine Immune Sciences and currently in Phase I for Systemic Lupus Erythematosus. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval. It is administered through intravenous and subcutaneous route.

Immunization 40

Immunization Pharmaceutical Companies Pharmaceutical Companies 40

pharmaphorum

DECEMBER 6, 2021

A trial of booster vaccinations to protect against COVID-19 has shown that the jab significantly strengthens the body’s T-cell immunity against the disease. All of these boosted immunity in younger and older people with varying efficacy. The post COVID booster shots increase immunity, trial shows appeared first on.

Immunization 52

Immunization Vaccines Hospitals 52

European Pharmaceutical Review

FEBRUARY 6, 2023

David Hallett, PhD, Chief Scientific Officer at Exscientia explained: “PKC theta is an attractive immune modulating drug target; however, it has been challenging for the field to design a small molecule with the required potency as well as selectivity against other closely related kinases.”

Compounding 91

Compounding Immunization 91

Outsourcing Pharma

JANUARY 30, 2023

The company will set up a clinical trial site network alongside sponsors, CROs, and health systems, for colorectal cancer and immune health.

Immunization 52

Immunization 52

Pharmacy Times

DECEMBER 13, 2023

Clinical trial results show the immunogenicity, tolerability, and safety of V116 compared to a pneumococcal 20-valent conjugate vaccine for adults who had not previously received a pneumococcal vaccine.

Vaccines 65

Vaccines Immunization 65

STAT

MAY 24, 2023

In particular, brain tumors are able to suppress the body’s immune activity and have comparably few genetic vulnerabilities that cancer drugs can target. ” That hasn’t stopped researchers from trying various ways to enlist the body’s own immune system to stamp out brain tumors.

Immunization 98

Immunization Vaccines 98

PharmaShots

APRIL 5, 2023

maintenance phase results showed a dose-linear increase in clinical remission, 10 & 30mg, qd of vidofludimus calcium showed clinical remission rate (42.3% & 61.5% vs 27.8%); steroid-free clinical remission rate (38.5% & 61.5% vs 27.8%); steroid-free clinical remission rate (38.5% & 61.5%

Immunization 40

Immunization 40

pharmaphorum

JANUARY 6, 2023

The cancer immunotherapies will mainly be provided in the context of clinical trials over the alliance, which extends out to 2030, but also covers supply of commercial therapies if approved in the interim. The post UK partners with BioNTech on clinical trials of mRNA cancer therapies appeared first on.

Vaccines 110

Vaccines Immunization 110

pharmaphorum

SEPTEMBER 23, 2020

Shares in AC Immune have collapsed after partner Genentech revealed its tau-targeting Alzheimer’s drug semorinemab had flunked a phase 2 trial in Alzheimer’s disease (AD). The post AC Immune poleaxed on Alzheimer’s study fail appeared first on.

Immunization 63

Immunization 63

Fierce Pharma

AUGUST 14, 2023

As layoffs continue to roil the biotech industry, bigger drugmakers and manufacturers such as Bristol Myers Sq | As layoffs continue to roil the biotech industry, bigger drugmakers and manufacturers like Bristol Myers Squibb and Emergent BioSolutions haven’t been immune.

Immunization 98

Immunization 98

pharmaphorum

APRIL 4, 2022

In particular, the findings suggest that disruption to innate immunity – the first line of defence against pathogens – as well as overly aggressive activity of white blood cells in the central nervous system called microglia. ” The post Study uncovers new Alzheimer’s genes, links to immune disruption appeared first on.

Immunization 52

Immunization 52

Pharmacy Times

JANUARY 26, 2024

Older patients’ underrepresentation in clinical trials leaves a gap in data regarding appropriate treatment.

Immunization 65

Immunization 65

European Pharmaceutical Review

FEBRUARY 7, 2023

MSD (Merck & Co) and Nectin Therapeutics have agreed to enter into a clinical trial collaboration, to investigate anti-PVR monoclonal antibody NTX1088 in combination with KEYTRUDA ® (pembrolizumab). PVR blockade by NTX1088 is the first and only therapeutic approach aiming at restoring the antitumor immune activity of DNAM1 (CD226).

Immunization 52

Immunization Labelling 52